Dr Neal Shore joins Clarity's Clinical Advisory Board
![]() |
SYDNEY, May 26, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that Dr Neal Shore has joined Clarity's Clinical Advisory Board (CAB).
Dr Shore MD, FACS is the Chief Medical Officer...
Read more: Dr Neal Shore joins Clarity's Clinical Advisory Board